SUPPLEMENTARY MATERIALS

Have fixed-duration (FD) regimens delivered on their promise in chronic lymphocytic leukemia and what is the future of FD regimens: a narrative review

Author: John N. Allan[1]

Affiliation: [1]Weill Cornell Medicine, New York, NY, USA

Corresponding author:

John N. Allan, MD

Associate Professor of Clinical Medicine

Weill Cornell Medicine

Division of Hematology & Medical Oncology

1305 York Ave. 7th Floor, Y766, New York, NY 10021

T:646-962-2064

F:646-962-1617

joa9069@med.cornell.edu

Supplemental Table S1. Follow-Up for Adverse Events

Parameter	CLL14	GLOW	CAPTIVATE FD	AMPLIFY	MURANO
Follow-up for AEs					
Any-grade TEAE	≤28 days after last venetoclax treatment; ≤90 days after last obinutuzumab treatment, whichever period is longer	≤30 days after last dose or 1 day prior to subsequent antineoplastic	≤30 days after last dose of ibrutinib or venetoclax, whichever occurs later, or start of new antineoplastic	≤30 days after last dose of study drug or at documented PD, whichever period is longer	≤28 days after last venetoclax treatment; ≤90 days after last rituximab treatment, whichever period is longer
Grade ≥3 AE	≤6 months after last study dose and grade ≥3infections for ≤2 years after the last dose of study drug	NA	NA	NA	NA
IRR	≤24 h post infusion	NA	NA	NA	≤24 h post infusion
SAE	≤1 year post treatment	NA	Reviewed on an ongoing basis	Indefinitely	NA
Treatment-related SAE (includes SPM)	Indefinitely	Up to end of study	Reviewed on an ongoing basis	Indefinitely	Indefinitely

AE, adverse event; IRR, infusion-related reaction; NA, not available; PD, progressive disease; SAE, serious adverse event; SPM, second primary malignancy; TEAE, treatment-emergent adverse event.